Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2023 16:01 ET | Source: FibroGen, Inc.

FibroGen Reports First Quarter 2023 Financial Results

• Topline Data From Four Phase 3 Trials Expected Through 3Q 2023 • Completed Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value • Entered Into...
April 24, 2023 07:00 ET | Source: FibroGen, Inc.

FibroGen to Report First Quarter 2023 Financial Results

SAN FRANCISCO, April 24, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2023 financial results on Monday, May 8 after the market close. FibroGen will also...
November 28, 2022 07:00 ET | Source: FibroGen, Inc.

FibroGen to Participate at Bank of America 2022 Biotech SMID Cap Virtual Conference

SAN FRANCISCO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Bank of...
August 08, 2022 16:01 ET | Source: FibroGen, Inc.

FibroGen Reports Second Quarter 2022 Financial Results

Completed enrollment of LELANTOS-2 Phase 3 study of pamrevlumab in ambulatory patients with Duchenne muscular dystrophy2Q 2022 revenue of $29.8 million, growth of 22% vs. 2Q 2021Continued significant...
July 01, 2022 07:00 ET | Source: FibroGen, Inc.

FibroGen to Participate at William Blair Biotech Focus Conference 2022

SAN FRANCISCO, July 01, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the William...
June 08, 2022 07:00 ET | Source: FibroGen, Inc.

FibroGen Announces Completion of Patient Enrollment in LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Duchenne Muscular Dystrophy

- 73 Ambulatory DMD Patients Enrolled -- Topline Data Anticipated 2H:2023 - SAN FRANCISCO, June 08, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient...
May 09, 2022 16:01 ET | Source: FibroGen, Inc.

FibroGen Reports First Quarter 2022 Financial Results

Completed enrollment in ZEPHYRUS-1 Phase 3 study of pamrevlumab in idiopathic pulmonary fibrosis1Q 2022 revenue of $60.8M, growth of 58% vs. 1Q 2021Significant roxadustat volume growth in China in...